Laura Leann Smith, APRN, FNP-C
Family · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Laura Leann Smith’s office at (415) 663-5584 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
$17,898
Pharmacies billed $17,898 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 92) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
67 generic and 25 brand-name prescriptions · $17,898 in drug cost · 17 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 15 | $16,008 | $1,067 |
| Fluoxetine | 11 | $70 | $6 |
Year by year
| 2024 | 92 | 32 | 0% (0) | 27% | $17,898 |
| 2023 | 55 | 20 | 0% (0) | 58% | $34,610 |
| 2021 | 13 | None | 0% (0) | None | $150 |
| 2020 | 15 | None | 0% (0) | None | $807 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Mounjaro | 20 | $22,297 | $1,115 |
| Ozempic | 11 | $10,645 | $968 |
Money from drug and device companies
$119 in 2025
| 2025 | 2 | 7 | None | $119 |
| 2024 | 5 | 5 | None | $170 |
| 2023 | 3 | 4 | None | $62 |
| 2022 | 1 | 1 | None | $12 |
| 2021 | 1 | 3 | None | $42 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $100 | 6 payments
|
| Stryker | Neptune | $19 | 1 payment
|
See all 7 published payments
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-10 | Caplyta | $21 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-12-09 | Caplyta | $16 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-11-19 | Caplyta | $18 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-14 | Caplyta | $14 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-07-28 | Caplyta | $15 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-24 | Caplyta | $15 |
| Stryker | Meals · 2025-02-10 | Neptune | $19 |
See earlier years (2024, 2023, 2022, 2021)
2024: $170
| Octapharma USA | Octagam Immune Globulin (Human) | $96 | 1 payment
|
| Lundbeck | Rexulti | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $21 | 1 payment
|
| Mirati Therapeutics | Krazati | $15 | 1 payment
|
| Stemline Therapeutics | Orserdu | $14 | 1 payment
|
2023: $62
| Mirati Therapeutics | Krazati | $28 | 2 payments
|
| Stemline Therapeutics | Orserdu | $20 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $15 | 1 payment
|
2022: $12
| Abbvie | Oriahnn | $12 | 1 payment
|
2021: $42
| AbbVie | Lo Loestrin Fe | $42 | 3 payments
|
Professional record
- NPI
- 1447892443
- Licence
- TX AP143157
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 555 Bryant St Ste 814, Palo Alto, CA, 94301
- NPI first listed
- 2019-10-10
- NPI last updated
- 2025-01-22
- NPI record certified
- 2025-01-22
This is when the NPI record was last certified, not a medical board exam.